SMALL SCALE PHARMA IN BIG TROUBLE

April 15th, 2016|

The pharmaceutical industry is growing bigger, more foreign players are entering the market, but that’s not good news for the small scale pharma industry. Small enterprises, mostly dependent on contract manufacture for larger companies are facing closure.

 

Whereas, the pharma market, currently worth around Rs 75,000 crore and growing towards Rs 100,000 crore, is opening up

FDA seeks $4.5 billion to promote public health

February 24th, 2012|

As a part of the President’s fiscal year (FY) 2013 budget the U.S. Food and Drug Administration has asked a budget of $4.5 billion on medical product development, protect patients and ensure safety of the food supply to support public health.

Size of Indian Pharma Market

January 3rd, 2012|

Structure / Market Size The US Sector $ 12 billion valued pharmaceutical industry in India is expected to grow at an compound annual growth rate (CAGR) of 10-11 per cent. The industry spends around 18 per cent of its revenue on research and development (R&D).

No place like home, finds Indian pharma

February 7th, 2010|

In a recent reversal, operations abroad are hampering profit.

Innovation is the key to pharma sector future 

February 7th, 2010|

The collapse of the property market has left the economy with a huge hole that will be difficult to fill. One of the few sectors that offers hope of growth is the pharmaceutical industry, with senior executives convinced that genuine opportunities remain for Ireland Inc.

Novartis to leapfrog Alcon deal

January 8th, 2010|

In one stroke, Swiss pharma giant Novartis AG could break into the league of top five players in the Rs 600-crore plus Indian eyecare market from its current position at 13, if its takeover of Alcon goes through seamlessly and eventually results in integration of Alcon India into the Indian arm of Novartis. Such a combined entity of Novartis and Alcon would then command a marketshare of 7.5% in the domestic eyecare market, just 1.4% less compared with the third and fourth ranked companies, FDC and Sun Pharma, which command 8.9% marketshare each.

GSK inching closer to deal with Dr Reddys?

January 8th, 2010|

Citing people familiar with the matter, pharmaquest.biz reported that Glaxo will take a 20-per cent stake in Dr. Reddy's Holdings Ltd., a family vehicle that owns 23.2 per cent of the Hyderabad-based Dr Reddy's Laboratories.

Bafna Pharma to focus mainly on life-style products

January 8th, 2010|

Bafna Pharmaceuticals,shall be focussing mainly on life-style products, the company chariman and managing director, Mahaveer Chand, disclosed, in an exclusive interview with pharmaquest.biz

Pharmaceutical sector has capacity to double exports in five years

January 7th, 2010|

* At least $1 billion incremental gains in export expected by 2014 Pakistan’s pharmaceutical sector has the potential to double its export in next five years provided pricing and contracting challenges are addressed in an efficient way, according to a draft of an official study.

Pharma cos see opportunity in India

January 5th, 2010|

The year had just begun, when Pfizer announced its $68-billion deal to acquire Wyeth, in January. On its heels came Merck & Co's $ 41-billion deal to acquire Schering-Plough Corporation, in March.

Despite slow growth, US stays drugmaker heaven

January 5th, 2010|

Lilliputs keep cropping up here and there, but can Gulliver be ignored?

Small players account for 40 percent of pharma ind

December 30th, 2009|

Few outside the recently developed township of Baddi in Himachal Pradesh will know Arun Rawat or his drug manufacturing company Kanha Biogenetic Laboratories. But this first-generation entrepreneur, who ventured into the drug-making business just five years ago, produces medicines for such majors as Wockhardt, Ajanta Pharma and Ind-Swift, to name a few.

Drug firms seeking panacea

December 28th, 2009|

Many shifting focus to emerging economies in struggle to stay afloatMajor Japanese pharmaceutical makers are expediting projects to construct plants and expand sales channels in emerging economies, such as China and India.

Dr Reddys all set to become 3-billion US dollars Company

December 25th, 2009|

From the national independence in the late 40s, the Indian companies have acted in two ways – either forging partnership with a globally acclaimed conglomerate or remaining as the raw material supplier to any multinational corporation. But now, it seems, those days are gone and Indian companies are desirous to capitalize on the changing worldwide fiscal scenario and Dr. Reddy’s Laboratories, Indian pharma major, is set to be the vanguard. How?

Daiichi to use Ranbaxy network in Africa

December 21st, 2009|

After East Europe and Mexico, Daiichi Sankyo, which bought out Ranbaxy Labs Ltd last year, is all set to leverage the latter’s marketing and distribution strength in six countries of Africa. This is the third instance in the last four months where Ranbaxy is helping Daiichi create a presence and consolidate its position in new emerging markets.

Dr Reddys eyes brand buys in Russia, new launches here

December 21st, 2009|

DR REDDY’S Laboratories plans to buy brands in Russia and introduce new products in India as it plans to scale up businesses in key emerging markets, a top company executive said.

Indian drugmakers leap ahead with Big Pharma

December 21st, 2009|

Big Pharma made this a big year for Indian drugmakers. As multinational companies sought ways to cut costs and grow revenues, they ramped up their outsourcing programs and partnerships–and that has helped push sales growth past 20 percent for India's leading drugmakers, such as Ranbaxy Laboratories, Cipla, Dr Reddy's Laboratories, and Aurobindo Pharma, according to the report.

Top pharma cos step up R and D spending to boost presence in regulated, emerging markets

December 20th, 2009|

India's pharmaceutical sector has stepped up its research & development expenditure in a bid to capture a larger market share in highly regulated and emerging markets.

Era of big-ticket pharma buys fading

December 20th, 2009|

In a sector that is seeing more inbound acquisitions of late, the latest being the Hospira-Orchid deal, the zeal to pursue large outbound acquisitions would be restricted for some time at least.

Outsourcing steroid for Indian pharma firms

December 20th, 2009|

Global multinational drug companies need to outsource manufacturing to low-cost destinations like India has turned out to be a boon for leading drug companies in India such as Ranbaxy, Cipla, Dr Reddy’s Laboratories and Aurobindo.